Role of Circulating Biomarkers in Diabetic Cardiomyopathy
Rattachement africain : ro. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that has alarmingly increased in incidence in recent decades. One of the most serious complications of T2DM is diabetic cardiomyopathy (DCM), an often underrecognized yet severe condition that is a leading cause of mortality among diabetic patients. In the early stages of DCM, patients typically show no symptoms and maintain normal systolic and diastolic left ventricle function, making early detection challenging. Currently available clinical markers are often not specific enough to detect the early stage of DCM. Conventional biomarkers of cardiac mechanical stress and injury, such as natriuretic peptides (NPs) and cardiac troponin I (cTnI), have shown limited predictive value for patients with T2DM. NPs have proven efficacy in detecting diastolic dysfunction in diabetic patients when used alongside 2D echocardiography, but their utility as biomarkers is limited to symptomatic individuals. While cTnI is a reliable indicator of general cardiac damage, it is not specific to cardiac injury caused by high glucose levels or T2DM. This underscores the need for research into biomarkers that can enable early diagnosis and management of DCM to reduce mortality rates. Promising novel biomarkers that showed good performance in detecting diastolic dysfunction or heart failure in diabetic patients include galectin-3, ST2, FGF-21, IGFBP-7, GDF-15, and TGF-β. This review summarizes the current understanding of DCM biomarkers, aiming to generate new ideas for the early recognition and treatment of DCM by exploring related pathophysiological mechanisms.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Role of Circulating Biomarkers in Diabetic Cardiomyopathy
- Date Crossref
- 23/09/2024
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Iuliu Hațieganu University of Medicine and Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Vasile Goldis Western University of Arad pays non établi dans la noticeUniversité ou école supérieure
-
“Iuliu Hațieganu” University of Medicine and Pharmacy Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmacy Department of Pharmaceutical Biochemistry and Clinical Laboratory pays non établi dans la noticeUniversité ou école supérieure
-
Emergency County Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Faculty of Medicine Arad pays non établi dans la noticeUniversité ou école supérieure
-
University of Medicine and Pharmacy “Iuliu Hațieganu” Department of Medical Biochemistry pays non établi dans la noticeUniversité ou école supérieure
Iuliu Hațieganu University of Medicine and Pharmacy, Vasile Goldis Western University of Arad et Department of Cardiology — “Iuliu Hațieganu” University of Medicine and Pharmacy, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.